The human genome encodes 40 voltage-gated K + channels (K V), which are involved in diverse physiological processes ranging from repolarization of neuronal and cardiac action potentials, to regulating Ca 2+ signalling and cell volume, to driving cellular proliferation and migration. KV channels offer tremendous opportunities for the development of new drugs to treat cancer, autoimmune diseases and metabolic, neurological and cardiovascular disorders. This Review discusses pharmacological strategies for targeting KV channels with venom peptides, antibodies and small molecules, and highlights recent progress in the preclinical and clinical development of drugs targeting the K V 1 subfamily, the KV 7 subfamily (also known as KCNQ), KV 10.1 (also known as EAG1 and KCNH1) and KV 11.1 (also known as HERG and KCNH2) channels.
ASJC Scopus subject areas
- Drug Discovery